Novel microsomal triglyceride transfer protein inhibitors

Expert Opinion on Therapeutic Patents

Volumn 13, Issue 4, 2003, Pages 479-488

  Williams, Spencer J ^a   Best, James D ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Apolipoprotein B (ApoB); Chylomicron; Microsomal triglyceride transfer protein (MTP); Triglyceride; Vero low density lipoprotein (VLDL)

Indexed keywords

AGENTS AFFECTING LIPID METABOLISM; ANILINE DERIVATIVE; ANTIOBESITY AGENT; APOLIPOPROTEIN B; BAY 139952; BENZIMIDAZOLE DERIVATIVE; BMS 200150; BMS 201038; BMS 212122; CHYLOMICRON; CYCLOPEPTIDE; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDRAZIDE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMPLITAPIDE DERIVATIVE; INDAN DERIVATIVE; ISOINDOLE DERIVATIVE; ISOINDOLONE DERIVATIVE; LOW DENSITY LIPOPROTEIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIPERAZINE DERIVATIVE; PROTEIN INHIBITOR; QUINAZOLINONE DERIVATIVE; ROSIGLITAZONE; SIBUTRAMINE; TETRAHYDROISOQUINOLINE DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CHEMICAL BINDING; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; DYSLIPIDEMIA; GASTROINTESTINAL SECRETION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPID ABSORPTION; LIPID METABOLISM; LIPID TRANSPORT; LIVER METABOLISM; MICROSOME; MOUSE; NONHUMAN; REVIEW; SIDE EFFECT;

EID: 0037398342     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.13.4.479     Document Type: Review

References (49)

1. CONNOR SL, GUSTAFSON JR, ARTAUD-WILD SM et al.: The cholesterol/saturated-fat index: an indication of the hypercholesterolaemic and atherogenic potential of food. Lancet (1986) 1(8492):1229-1232.
2. AUSTIN MA, HOKANSON JE, EDWARDS KL: Hypertriglyceridemia as a cardiovascular risk factor. Am. J. Cardiol. (1998) 81(4A):7B-12B.
3. ASSMANN G, SCHULTE H: Role of triglycerides in coronary artery disease: lessons from the prospective cardiovascular Münster study. Am. J. Cardiol. (1992) 70(19): 10H-13H.
4. SCHAEFER EJ, LEVY RI: Pathogenesis and management of lipoprotein disorders. N. Engl. J. Med. (1985) 312:1300-1310.
5. ILLINGWORTH DR: Lipoprotein metabolism. Am. J. Kidney Dis. (1993) 22:90-97.
6. YOUNG SG: Recent progress in understanding apolipoprotein B. Circulation (1990) 82:1574-1594.
7. UTERMANN G: The mysteries of lipoprotein (a). Science (1989) 246:904-910.
8. KNIGHT BL: Lp(a) catabolism in hypercholesterolaemic individuals. Chem. Phys. Lipids (1994) 67-68:233-239.
9. WILSON PW, D'AGOSTINO RB, LEVY D, BELANGER AM, SELBERSHATZ H, KANNEL WB: Prediction of coronary heart disease using risk factor categories. Circulation (1998) 97:1837-1847.
10. TOLLESHAUG H, HOBGOOD KK, BROWN MS, GOLDSTEIN JL: The LDL receptor locus in familial hypercholesterolemia: multiple mutations disrupt transport and processing of a membrane receptor. Cell (1983)32:941-951.
11. KOSTNER KM, KOSTNER GM: Lipoprotein(a): still an enigma. Curr. Opin. Lipidol. (2002) 13:391-396.
12. KRAUSS RM: Atherogenicity of triglyceride-rich lipoproteins. Am. J. Cardiol. (1998) 81(4A):13B-17B.
13. GOLDSTEIN JL, SCHROTT HG, HAZZARD WR, BIERMAN EL, MOTULSKY AG: Hyperlipidemia in coronary heart disease. II. Genetic analysis in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J. Clin. Invest. (1973) 52:1544-1568.
14. VENKATESAN S, CULLEN P, PACY P, HALLIDAY D, SCOTT J: Stable isotopes show a direct relation between VLDL ApoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler. Thromb. (1993) 13:1110-1118.
15. KWITEROVICH PO: Clinical relevance of the biochemical, metabolic, and genetic factors that influence flow-density lipoprotein heterogeneity. Am. J. Cardiol. (2002) 90(8A):30i-47i.
16. RUOTOLO G, HOWARD BV: Dyslipidemia of the metabolic syndrome. Curr. Cardiol. Rep. (2002) 4:494-500.
17. GENEST J, NGUYEN NH, THEROUX P, DAVIGNON J, COHN JS: Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state. J. Cardiovasc. Pharmacol. (2000) 35:164-172.
18. GORDON DA, JAMIL H: Progress towards understanding the role of microsomal triglyceride transfer protein in apolipoprotein-B lipoprotein assembly. Biochim. Biophys. Acta (2000) 1486:72-83.
19. LEVY E, STAN S, DELVIN E et al.: Localization of microsomal triglyceride transfer protein in the Golgi: possible role in the assembly of chylomicrons. J. Biol. Chem. (2002) 277:16470-16477.
20. LIANG J, GINSBERG HN: Microsomal triglyceride transfer protein binding and lipid transfer activities are independent of each other, but both are required for secretion of apolipoprotein B lipoproteins from liver cells. J. Biol. Chem. (2001) 276:28606-28612.
21. WETTERAU JR, LIN MCM, JAMIL H: Microsomal triglyceride transfer protein. Biochim. Biophys. Acta. (1997) 1345:136-150.
22. WETTERAU JR, COMBS KA, SPINNER SN, JOINER BJ: Protein disulfide isomerase is a component of the microsomal triglyceride transfer protein complex. J. Biol. Chem. (1990) 265:9801-9807.
23. DASHTI N, GANDHI M, LIU X, SEGREST JP: The N-terminal 1000 residues of apolipoprotein B associate with microsomal triglyceride transfer protein to create a lipid transfer pocket required for lipoprotein assembly. Biochemistry (2002) 41:6978-6987.
24. SHELNESS GS, SELLERS JA: Very-low-density lipoprotein assembly and secretion. Curr. Opin. Lipidol. (2001) 12:151-157.
25. HAGAN DL, KIENZLE B, JAMIL H, HARIHARAN N: Transcriptional regulation of human and hamster microsomal triglyceride transfer protein genes. Cell type-specific expression and response to metabolic regulators. J. Biol. Chem. (1994) 269:28737-28744.
26. RAABE M, FLYNN LM, ZLOT CH et al.: Knockout of the abetalipoproteinemia gene in mice: reduced lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes. Proc. Natl. Acad. USA (1998) 95:8686-8691.
27. WETTERAU JR, AGGERBECK LP, BOUMA ME et al.: Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science (1992) 258:999-1001.
28. RADER DJ, BREWER HB Jr: Abetalipoproteinemia: new insights into lipoprotein assembly and vitamin E metabolism from a rare genetic disease. JAMA (1993) 270:865-869.
29. KARPE F, LUNDAHL B, EHRENBORG E, ERIKSSON P, HAMSTEN A: A common functional polymorphism in the promoter region of the microsomal triglyceride transfer protein gene influences plasma LDL levels. Arterioscler. Tbromb. Vasc. Biol. (1998) 18:756-761.
30. JAMIL H, GORDON DA, EUSTICE DC et al.: An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells. Proc. Natl. Acad. Sci. USA (1996) 93:11991-11995.
31. ARROL S, MACKNESS MI, DURRINGTON PN: The effects of fatty acids on apolipoprotein B secretion by human hepatoma cells (HEP G2). Atherosclerosis (2000) 150:255-264.
32. BAKILLAH A, NAYAK N, MEDFORD RM, HUSSAIN MM: Decreased secretion of ApoB follows inhibition of ApoB-MTP binding by a novel antagonist. Biochemistry (2000) 39:4892-4899.
33. CARDOZO C, WU X, PAN M, WANG H, FISHER EA: The inhibition of microsomal triglyceride transfer protein activity in hepatoma cells promotes proteasomal and non-proteasomal degradation of apoprotein B100. Biochemistry (2002) 41:10105-10114.
34. CHANG G, RUGGERI RB, HARWOOD HJ: Microsomal triglyceride transfer protein (MTP) inhibitors: discovery of clinically active inhibitors using high-throughput screening and parallel synthesis paradigms. Curr. Opin. Drug Discov. Devel. (2002) 5:562-570.
35. WETTERAU JP, GREGG RE, HARRITY TW et al.: An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science (1998) 282:751-754.
36. ROBL JA, SULSKY R, SUN CQ et al.: A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors. J. Med. Chem. (2001) 44:851-856.
37. KSANDER GM, DEJESUS R, YUAN A et al.: Diaminoindanes as microsomal triglyceride transfer protein inhibitors. J. Med. Chem. (2001) 44:4677-4687.
38. LIAO W, HUI TY, YOUNG SG, DAVIS R: Blocking microsomal triglyceride transfer protein interferes with apolipoprotein B secretion without causing retention or stress in the endoplasmic reticulum. J. Lipid Res. (2003) [Electronically published ahead of print].
39. SHIOMI M, ITO T: MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion. Eur. J. Pharmacol. (2001) 431:127-131.
40. WETTERAU JR, ZILVERSMIT DB: Localization of intracellular triacylglycerol and cholesteryl ester transfer activity in rat tissues. Biochim. Biophys. Acta (1986) 875:610-617.
41. NIELSEN LB, VENIANT M, BOREN J et al.: Genes for apolipoprotein B and microsomal triglyceride transfer protein are expressed in the heart: evidence that the heart has the capacity to synthesize and secrete lipoproteins. Circulation (1998) 98:13-16.
42. GOTTO AM: Risk factor modification: rationale for management of dyslipidemia. Am. J. Med. (1998) 104(2A):6S-8S.
43. CROUSE JR: Effects of statins on carotid disease and stroke. Curr. Opin. Lipidol. (1999) 10:535-541.
44. CHAPMAN MJ, CASLAKE M, PACKARD C, MCTAGGART F: New dimension of statin action on Apo B atherogenicity. Clin. Cardiol. (2003) 26(Suppl.1):17-110.
45. CHAN DC, WATTS GF, REDGRAVE TG, MORI TA, BARRETT PH: Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism (2002) 51:1041-1046.
46. GINSBERG HN, ILLINGWORTH DR: Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus. Am. J. Cardiol. (2001) 88(6A):9H-15H.
47. BJORKEGREN J, BEIGNEUX A, BERGO MQ, MAHER JJ, YOUNG SG: Blocking the secretion of hepatic very low density lipoproteins renders the liver more susceptible to toxin-induced injury. J. Biol. Chem. (2002) 277:5476-5483.
48. BJORKEGREN J, VENIANT M, KIM SK et al.: Lipoprotein secretion and triglyceride stores in the heart. J. Biol. Chem. (2001) 276:38511-38517.
49. HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360:7-22.